Skip to main content

Table 9 Study B and Study C– Summary of efficacy outcomes imparted by the bivalent vaccine compared to monovalent vaccines for Studies B and C

From: A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines

Protection Endpoint

% Improvement of PCV2a-PCV2b bivalent vs:

PCV2a monovalent2

PCV2b monovalent2

Viremia

28.3%

21.9%

Fecal Shedding

29.9%

4.5%

Lymphoid Depletion (LD)1

68.5%

25.1%

Histiocytic Replacement (HR) 1

NA

100%

LD or HR1

68.5%

24.5%

Lymphoid Colonization (IHC) 1

53.3%

37.5%

Serology1*

17.7%

32.7%

  1. 1 Presented as back-transformed least square means.
  2. *The ELISA used to determine PCV2 specific antibodies (serology) was an S/N (sample to negative ratio) ELISA where seropositive < 0.5. Serology data noted are from a blood sample collected at necropsy.
  3. 2 The percent improvement of the bivalent vaccine over the monovalent vaccine has been calculated for each outcome criteria ((monovalent-bivalent)/monovalent).
Back to article page

Veterinary Research

ISSN: 1297-9716